Ivermectin and Cancer: What the Science Really Says

For decades, ivermectin was known as one thing: a remarkably safe antiparasitic drug that has protected millions of people from diseases like river blindness and scabies. Its discoverers, William Campbell and Satoshi Ōmura, were awarded the 2015 Nobel Prize in Physiology or Medicine for its impact on global health. Then researchers started looking more closely at what it was actually doing inside human cells — and the findings were surprising.

Today, ivermectin is one of the most actively discussed repurposed drugs in oncology research. A 2024 systematic review in Pharmaceutics analyzed dozens of preclinical and clinical studies and concluded that ivermectin demonstrates "multi-targeted anticancer activity" across a range of cancer types [1]. This is not a fringe theory — it is a growing body of peer-reviewed molecular biology, cell culture work, animal models, and now early human trial data.

This article examines what the science actually shows: the molecular mechanisms, the cancer types studied, the clinical trials underway, realistic dosing frameworks used in research settings, and the safety considerations anyone researching this topic should understand. For readers exploring related repurposed-drug protocols, see our companion pieces on the fenbendazole cancer protocol, the Joe Tippens protocol, and the fenbendazole–ivermectin combination.

What Is Drug Repurposing, and Why Does It Matter in Oncology?

Drug repurposing — using an approved medication for a new indication — has produced some of oncology's most important breakthroughs. Thalidomide, once withdrawn as a sedative due to teratogenicity, is now a first-line treatment for multiple myeloma. Metformin, a decades-old diabetes medication, is being studied in dozens of active cancer prevention and adjuvant treatment trials. Aspirin is under investigation for colorectal cancer chemoprevention. Even chloroquine, an antimalarial, has been explored as an autophagy modulator in combination oncology regimens.

The appeal of repurposing is straightforward: these drugs already have decades of human safety data, known pharmacokinetics, established manufacturing, and low cost. The scientific risk is different from that of a novel compound — the primary open question is efficacy at the right dose and combination, not basic human tolerability.

Ivermectin fits this pattern precisely. It has been administered to an estimated 3.7 billion doses worldwide through mass drug administration campaigns for onchocerciasis and lymphatic filariasis, giving researchers an unusually large safety dataset to draw from as they explore new applications [1].

7 Ways Ivermectin Targets Cancer Cells

What makes ivermectin scientifically interesting in oncology is not a single mechanism but a converging set of molecular actions that touch several of the "hallmarks of cancer" described by Hanahan and Weinberg — sustained proliferation, evasion of apoptosis, immune evasion, and drug resistance.

1. It Blocks MDR — The "Chemo Escape" Mechanism

One of the biggest reasons cancer becomes resistant to chemotherapy is a transmembrane protein called P-glycoprotein (P-gp, encoded by the ABCB1 gene), sometimes called the "multidrug resistance pump." It physically pumps chemotherapy drugs — including doxorubicin, paclitaxel, and vincristine — out of cancer cells before they can exert cytotoxic effects.

Ivermectin is one of the most potent known inhibitors of P-gp — outperforming verapamil, the classic reference compound used in multidrug-resistance (MDR) research, in several in vitro assays [2]. Jiang et al. (2019) demonstrated that ivermectin reversed drug resistance in cancer cells through modulation of the EGFR/ERK/Akt/NF-κB signaling axis, restoring chemosensitivity in previously resistant cell lines [2]. In practical terms, this means ivermectin may help chemotherapy drugs stay inside cancer cells longer, potentially re-sensitizing tumors that have stopped responding to standard regimens — a property with direct clinical implications for relapsed or refractory disease.

2. It Shuts Down the Wnt/β-Catenin Pathway

The Wnt/β-catenin pathway is a master regulator of cancer cell proliferation, stemness, and metastasis. It is aberrantly activated in an estimated 80% of colorectal cancers, and plays a major role in triple-negative breast cancer (TNBC), gastric cancer, and hepatocellular carcinoma.

Diao et al. (2022), published in Stem Cell Reports, showed that ivermectin suppresses canonical Wnt signaling by directly binding to TELO2, a scaffolding protein involved in the DNA damage response and PIKK kinase stability. This binding destabilizes β-catenin, reduces its nuclear translocation, and blocks transcription of Wnt target genes such as c-Myc and cyclin D1 — effectively shutting down one of the primary engines of tumor growth in TNBC stem-like cells [3].

3. It Degrades PAK1 — An Oncogenic Kinase

PAK1 (p21-activated kinase 1) is overexpressed in ovarian cancer, breast cancer, lung cancer, pancreatic cancer, and neurofibromatosis type 2 (NF2)-related tumors. It functions as a convergence point for RAS, PI3K, and other growth-signaling cascades — essentially a master switch coordinating multiple pro-tumor programs simultaneously.

Hashimoto et al. (2012), in Drug Discovery & Therapeutics, found that ivermectin causes PAK1 to be ubiquitinated and degraded via the proteasome, effectively silencing this entire oncogenic axis. Their study showed dose-dependent inhibition of PAK1-dependent tumor cell growth in ovarian cancer and NF2 tumor models, with minimal effect on normal cells lacking PAK1 dependency [4].

4. It Triggers Immunogenic Cell Death

This may be ivermectin's most clinically exciting property. When cancer cells die via immunogenic cell death (ICD) — as opposed to "silent" apoptosis — they release damage-associated molecular patterns (DAMPs) including ATP, calreticulin, and HMGB1. These molecules act as alarm signals that recruit dendritic cells and activate cytotoxic T-lymphocytes against tumor antigens.

Research published in NPJ Breast Cancer demonstrated that ivermectin promoted CD8+ T-cell infiltration into immunologically "cold" breast tumors — tumors that typically evade immune surveillance and respond poorly to checkpoint inhibitors on their own. This mechanistic insight is what directly motivated the Cedars-Sinai clinical trial combining ivermectin with anti-PD-1 immunotherapy, since ICD-inducing agents are theorized to convert cold tumors into "hot" ones that are more responsive to checkpoint blockade.

5. It Inhibits YAP1 in Gastric Cancer

YAP1 (Yes-associated protein 1) is a transcriptional co-activator downstream of the Hippo signaling pathway that drives uncontrolled proliferation and resistance to contact inhibition. In gastric cancer, YAP1 overexpression correlates with poor prognosis and chemoresistance.

Zhang et al. (2018) found that ivermectin suppressed YAP1 activity in gastric cancer cell lines, and — notably — that sensitivity to ivermectin correlated directly with baseline YAP1 expression levels [8]. This raises the possibility that YAP1 expression could eventually serve as a predictive biomarker to identify which patients are most likely to benefit from ivermectin-based regimens, a precision-oncology angle that is still being explored.

6. It Induces Pyroptosis in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) — which lacks estrogen, progesterone, and HER2 receptors — is among the most difficult subtypes to treat because it cannot be targeted with hormone therapy or trastuzumab-class agents. Zheng et al. (2020), published in Cell Death & Disease, found that ivermectin induces pyroptosis, a highly inflammatory form of programmed cell death, specifically in TNBC cells via activation of the caspase-1/GSDMD (gasdermin D) pathway [5].

Unlike classic apoptosis, pyroptosis is lytic and pro-inflammatory — the cell membrane ruptures, releasing inflammatory cytokines (IL-1β, IL-18) that can further recruit immune cells to the tumor microenvironment. This mechanism dovetails with the immunogenic cell death pathway described above, suggesting ivermectin may create a double signal that both kills cancer cells directly and alerts the immune system to the attack.

7. It Disrupts the Nuclear Transport System

Cancer cells rely on rapid nuclear-cytoplasmic shuttling of transcription factors and signaling proteins to sustain their proliferative state. Ming et al. (2020), published in Pharmacological Research, showed that ivermectin disrupts this transport system by interfering with the importin α/β nuclear transport complex, blocking pro-oncogenic proteins from reaching the nucleus where they would otherwise activate transcription of growth-promoting genes [7]. This mechanism is shared with other repurposed antiparasitic agents under oncology investigation and is one reason ivermectin is sometimes studied alongside compounds like fenbendazole, which acts on microtubule dynamics through a different but complementary pathway — see our detailed breakdown in the fenbendazole–ivermectin combination article.

Cancer Types Where Ivermectin Has Been Studied

Preclinical data exists across a remarkably wide range of tumor types, reflecting the drug's multi-target profile rather than a single narrow mechanism:

• Breast cancer — including TNBC and hormone-resistant subtypes, via Wnt inhibition and pyroptosis induction
• Colorectal cancer — Wnt pathway hyperactivation is present in roughly 80% of cases
• Ovarian cancer — PAK1-dependent growth suppression
• Lung cancer — both NSCLC and SCLC preclinical models
• Gastric cancer — YAP1-correlated sensitivity
• Glioblastoma (GBM) — promising in vitro activity, though blood-brain barrier penetration remains a major caveat
• Chronic myeloid leukemia — early apoptosis-induction data
• Melanoma — combined cytotoxic and immune-modulatory effects
• Pancreatic cancer — one of the most treatment-resistant tumor types, under early exploration
• Prostate cancer — androgen-independent cell line studies

What Clinical Evidence Exists?

The honest answer: the clinical evidence is still early, but it is progressing from bench to bedside in a structured way.

The Cedars-Sinai Trial (NCT05318469): This is the most significant piece of ongoing clinical research on ivermectin in oncology. Cedars-Sinai Medical Center is running a Phase I/II study combining ivermectin with balstilimab, an anti-PD-1 checkpoint immunotherapy, in patients with metastatic triple-negative breast cancer — a population with historically poor response rates to checkpoint inhibition alone. Preliminary data published in 2025 showed the combination was safe and well-tolerated, with encouraging clinical benefit observed in a heavily pre-treated patient population [6]. This trial design directly follows from the immunogenic cell death mechanism described above: the hypothesis is that ivermectin's ability to make "cold" tumors immunologically "hot" could enhance the efficacy of PD-1 blockade.

The Observational Study (2026): A prospective cohort study of 197 cancer patients taking ivermectin in combination with mebendazole (another repurposed antiparasitic under oncology investigation) reported a Clinical Benefit Ratio of 84.4%, with 48.4% of patients showing tumor regression or no evidence of disease at the 6-month follow-up mark [9]. It is worth noting that observational cohort data of this kind lacks the randomization and control-arm comparison of a formal trial, so these figures should be interpreted as hypothesis-generating rather than definitive proof of efficacy.

Note: No large randomized controlled trial has yet established that ivermectin extends survival or produces durable remission in human cancer patients when used as a standalone agent. The current clinical evidence base consists of early-phase combination trials and observational cohorts — important early signals, but not yet a substitute for standard-of-care oncology treatment.

Dosing: What's Actually Being Used in Research Settings?

The standard FDA-approved antiparasitic dose is 150–200 mcg/kg, typically administered as a single dose or short course. In oncology research protocols, dosing tends to be repeated, higher, and structured around "pulse" cycles rather than one-time administration, based on pharmacokinetic modeling suggesting that intermittent high-exposure dosing may better achieve the plasma concentrations associated with anticancer activity in preclinical models.

The Cedars-Sinai trial, for example, uses ivermectin on days 1–3, 8–10, and 15–17 of each 21-day treatment cycle — a pulse-dose approach designed to balance sustained biological activity against cumulative toxicity risk. This is meaningfully different from the single-dose antiparasitic regimen most people are familiar with, and underscores why oncology-context dosing should never be self-directed without physician oversight.

Important pharmacokinetic note: Ivermectin is highly lipophilic. Taking it with a fatty meal significantly increases bioavailability — in some pharmacokinetic studies, absorption increased by roughly 2.5-fold when co-administered with a high-fat meal compared to a fasted state. Avoid high-concentration veterinary formulations (such as injectable or pour-on solutions intended for livestock); these are not designed, dosed, or purified for human administration and have caused serious poisonings when misused.

Many patients researching repurposed-drug protocols also look into combination frameworks such as the Joe Tippens protocol, which pairs fenbendazole with other agents, or structured comparisons in our fenbendazole cancer protocol guide. These frameworks are patient-driven and anecdotal in origin — they are not clinical guidelines, and should be discussed with an oncology team before adoption.

Safety Considerations

Ivermectin has an excellent safety profile at approved antiparasitic doses, supported by billions of administered doses globally. That said, oncology-context use — which often involves higher, repeated dosing — carries risks that differ from the standard single-dose antiparasitic use case:

• Neurotoxicity at high doses: Ivermectin is normally excluded from the central nervous system by P-glycoprotein at the blood-brain barrier. At very high doses, or in individuals with ABCB1 gene mutations (which reduce P-gp function), brain concentrations can rise to neurotoxic levels, producing symptoms ranging from dizziness and ataxia to, in severe cases, coma.
• Warfarin interaction: Case reports have documented elevated INR (International Normalized Ratio) in patients taking ivermectin alongside warfarin, raising bleeding risk. Patients on anticoagulant therapy require closer monitoring if considering ivermectin use.
• Veterinary formulations: Concentrated veterinary injectable or pour-on solutions are formulated for animal body weights and are not appropriate for human dosing under any circumstance.
• Hepatic considerations: Ivermectin is metabolized hepatically via CYP3A4; patients with significant liver impairment or those on other CYP3A4-interacting medications (common in cancer regimens) should have dosing reviewed by their care team.
• Drug-drug interactions in active cancer treatment: Because many chemotherapy and targeted agents are also P-gp substrates, ivermectin's potent P-gp inhibition — while mechanistically interesting for reversing resistance — also means it can alter the pharmacokinetics of concurrently administered cancer drugs. This is precisely why any combination use requires oncologist supervision rather than independent experimentation.

The Bottom Line

Ivermectin is not a replacement for oncology care, and no regulatory body has approved it as a cancer treatment. But it is a molecule with a genuinely remarkable multi-target profile, an excellent safety record at standard antiparasitic doses, and growing clinical interest supported by mechanistic plausibility across at least seven distinct pathways — from P-glycoprotein inhibition and Wnt/β-catenin suppression to immunogenic cell death and pyroptosis induction.

The research community has noticed. The Cedars-Sinai trial represents a meaningful step from cell-culture data toward structured clinical evaluation, and observational cohort data — while methodologically limited — adds to a growing signal worth continued study. The clinical trial pipeline is building, but it remains early. For patients who are exploring every option, understanding the actual science — its strengths and its current limitations — is the responsible first step, always in partnership with an oncology team.

Recommended Products

All products are independently lab-tested for purity (99%+) and ship from the United States.

Frequently Asked Questions